PPARG and liposarcoma: The PPAR-gamma agonist troglitazone was used for the treatment of patients with advanced liposarcoma and demonstrated expression of several mRNA transcripts characteristic of adipocytic differentiation and a marked reduction in cancer cell proliferation [123].